Abstract:BACKGROUND: Endothelial dysfunction, a hallmark of diabetes, is a critical and initiating contributor to the pathogenesis of diabetic cardiovascular complications. However, the underlying mechanisms are still not fully understood. Ferroptosis is a newly defined regulated cell death driven by cellular metabolism and iron-dependent lipid peroxidation. Although the involvement of ferroptosis in disease pathogenesis has been shown in cancers and degenerative diseases, the participation of ferroptosis in the pathogenesis of diabetic endothelial dysfunction remains unclear.AIM: To examine the role of ferroptosis in diabetes-induced endothelial dysfunction and the underlying mechanisms.METHODS: Human umbilical vein endothelial cells (HUVECs) were treated with high glucose (HG), interleukin-1β (IL-1β), and ferroptosis inhibitor, and then the cell viability, reactive oxygen species (ROS), and ferroptosis-related marker protein were tested. To further determine whether the p53-xCT (the substrate-specific subunit of system Xc<sup>-</sup>)-glutathione (GSH) axis is involved in HG and IL-1β induced ferroptosis, HUVECs were transiently transfected with p53 small interfering ribonucleic acid or NC small interfering ribonucleic acid and then treated with HG and IL-1β. Cell viability, ROS, and ferroptosis-related marker protein were then assessed. In addition, we detected the xCT and p53 expression in the aorta of db/db mice.RESULTS: It was found that HG and IL-1β induced ferroptosis in HUVECs, as evidenced by the protective effect of the ferroptosis inhibitors, Deferoxamine and ferrostatin-1, resulting in increased lipid ROS and decreased cell viability. Mechanistically, activation of the p53-xCT-GSH axis induced by HG and IL-1β enhanced ferroptosis in HUVECs. In addition, a decrease in xCT and the presence of de-endothelialized areas were observed in the aortic endothelium of db/db mice.CONCLUSION: Ferroptosis is involved in endothelial dysfunction and p53-xCT-GSH axis activation plays a crucial role in endothelial cell ferroptosis and endothelial dysfunction.

Design, synthesis, and evaluation of novel ferrostatin derivatives for the prevention of HG-induced VEC ferroptosis

Design, synthesis, and evaluation of formylpiperazine analogs of Ferrostatin-1 as novel improved ferroptosis inhibitors

Synthesis and biological evaluation of ferrostatin-based diamide derivatives as new ferroptosis inhibitors

Design and Synthesis of 1,4‐Diformyl‐Piperazine Ferrostatin‐1 Derivatives as Novel Ferroptosis Inhibitors

Design, Synthesis, and Biological Evaluation of New Improved Ferrostatin‐1 Derived Ferroptosis Inhibitors

Vitexin ameliorated diabetic nephropathy via suppressing GPX4-mediated ferroptosis

Protecting against ferroptosis in hyperuricemic nephropathy: The potential of ferrostatin-1 and its inhibitory effect on URAT1

In vivo assembly enhanced binding effect augments tumor specific ferroptosis therapy

Design, synthesis, and biological evaluation of 2-amino-6-methyl-phenol derivatives targeting lipid peroxidation with potent anti-ferroptotic activities

Ferroptosis: A Novel Anti-tumor Action for Cisplatin

Vitexin attenuates chronic kidney disease by inhibiting renal tubular epithelial cell ferroptosis via NRF2 activation

Role of ferroptosis in the process of diabetes-induced endothelial dysfunction

Mechanism of Ferroptosis: A Potential Target for Cardiovascular Diseases Treatment

Ferroptosis in life: To be or not to be

Application of natural products for inducing ferroptosis in tumor cells

Inhibiting ferroptosis: A novel approach for stroke therapeutics

Highly selective and effective ferroptosis liposomal nanodrugs for synergistic antitumor therapy

Ferroptosis inhibitors: past, present and future

Targeting Ferroptosis As a Potential Prevention and Treatmentstrategy for Human Diseases

Nanovesicle-templated Nanogel: A Dual-Modal Platform Integrating Intracellular Iron Homeostasis Disruption for Ferroptosis and MRI-guided Tumor Diagnosis

Advances in ferroptosis of cancer therapy